73(top 5%)
PR articles
12.9K(top 1%)
PR citations
44(top 1%)
PR h-index
48(top 1%)
h-index
89
documents
15.8K
doc citations
2.0K
citing journals
100
times ranked

Publications

77 peer-reviewed articles • 13,748 peer-reviewed citations • Sorted by year • Download PDF (PDF by citations)
Sort: Year | Citations
#ArticleIFCitationsLinks
1Aging, cellular senescence and Parkinson's disease
Journal of Parkinson's Disease, 2025, 15, 239-254
2.236Citations (PDF)
2Pathological α-synuclein elicits granulovacuolar degeneration independent of tau
Translational Neurodegeneration, 2025, 14, 31
8.33Citations (PDF)
3VPS35 and retromer dysfunction in Parkinson's disease
Philosophical Transactions of the Royal Society B: Biological Sciences, 2024, 379, 20220384
2.621Citations (PDF)
4Adult-onset deletion of ATP13A2 in mice induces progressive nigrostriatal pathway dopaminergic degeneration and lysosomal abnormalities
Npj Parkinson's Disease, 2024, 10, 1-12
4.518Citations (PDF)
5Heterozygous loss of and α-synucleinopathy (En1/SYN): A dual-hit preclinical mouse model of Parkinson's disease, analyzed with artificial intelligence
Neurobiology of Disease, 2024, 200, 106647
3.63Citations (PDF)
6Neuropathology in an α-synuclein preformed fibril mouse model occurs independent of the Parkinson's disease-linked lysosomal ATP13A2 protein
Neurobiology of Disease, 2024, 202, 106701
3.611Citations (PDF)
7VPS35 and α-Synuclein fail to interact to modulate neurodegeneration in rodent models of Parkinson’s disease
Molecular Neurodegeneration, 2023, 18, 1-20
9.810Citations (PDF)
8Hippocampal subfield vulnerability to α-synuclein pathology precedes neurodegeneration and cognitive dysfunction
Npj Parkinson's Disease, 2023, 9, 1-11
4.530Citations (PDF)
9Formation of templated inclusions in a forebrain α-synuclein mouse model is independent of LRRK2
Neurobiology of Disease, 2023, 188, 106338
3.64Citations (PDF)
10Understanding the contributions of VPS35 and the retromer in neurodegenerative disease
Neurobiology of Disease, 2022, 170, 105768
3.651Citations (PDF)
11Log in to my account
Journal of Parkinson's Disease, 2022, 12, 1423-1447
2.215Citations (PDF)
12Neuronal VPS35 deletion induces spinal cord motor neuron degeneration and early post-natal lethality.
Brain Communications, 2021, 3, fcab208
2.024Citations (PDF)
13Multiple genetic pathways regulating lifespan extension are neuroprotective in a G2019S LRRK2 nematode model of Parkinson's disease
Neurobiology of Disease, 2021, 151, 105267
3.616Citations (PDF)
14Log in to my account
Journal of Parkinson's Disease, 2020, 10, 1271-1291
2.296Citations (PDF)
15People also looked at
Frontiers in Neuroscience, 2020, 14, 558161
2.026Citations (PDF)
16Dopaminergic neurodegeneration induced by Parkinson's disease-linked G2019S LRRK2 is dependent on kinase and GTPase activity
Proceedings of the National Academy of Sciences of the United States of America, 2020, 117, 17296-17307
5.362Citations (PDF)
17Time course and magnitude of alpha-synuclein inclusion formation and nigrostriatal degeneration in the rat model of synucleinopathy triggered by intrastriatal α-synuclein preformed fibrils
Neurobiology of Disease, 2019, 130, 104525
3.6107Citations (PDF)
18Parkinson’s disease-linked D620N VPS35 knockin mice manifest tau neuropathology and dopaminergic neurodegeneration
Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 5765-5774
5.3111Citations (PDF)
19Pathogenic alpha-synuclein aggregates preferentially bind to mitochondria and affect cellular respiration
Acta Neuropathologica Communications, 2019, 7, 1-14
3.4203Citations (PDF)
20G2019S LRRK2 enhances the neuronal transmission of tau in the mouse brain.
Human Molecular Genetics, 2018, 27, 120-134
2.149Citations (PDF)
21Deciphering the role of VPS35 in Parkinson's disease
Journal of Neuroscience Research, 2018, 96, 1339-1340
2.04Citations (PDF)
22Parkin mediates the ubiquitination of VPS35 and modulates retromer-dependent endosomal sorting
Human Molecular Genetics, 2018, 27, 3189-3205
2.167Citations (PDF)
23Parkin functionally interacts with PGC-1α to preserve mitochondria and protect dopaminergic neurons
Human Molecular Genetics, 2017, 26, 582-598
2.160Citations (PDF)
24Mechanisms of LRRK2-dependent neurodegeneration: role of enzymatic activity and protein aggregation
Biochemical Society Transactions, 2017, 45, 163-172
2.764Citations (PDF)
25Log in to my account
Journal of Parkinson's Disease, 2017, 7, 219-233
2.2158Citations (PDF)
26Ubiqutination via K27 and K29 chains signals aggregation and neuronal protection of LRRK2 by WSB1
Nature Communications, 2016, 7, 1-11
11.076Citations (PDF)
27Guidelines for the use and interpretation of assays for monitoring autophagy (3rd edition)
Autophagy, 2016, 12, 1-222
12.05,058Citations (PDF)
28Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease
Neurobiology of Disease, 2015, 77, 49-61
3.648Citations (PDF)
29α-Synuclein-induced dopaminergic neurodegeneration in a rat model of Parkinson's disease occurs independent of ATP13A2 (PARK9)
Neurobiology of Disease, 2015, 73, 229-243
3.641Citations (PDF)
30Functional interaction of Parkinson's disease-associated LRRK2 with members of the dynamin GTPase superfamily.
Human Molecular Genetics, 2014, 23, 2055-77
2.1129Citations (PDF)
31Parkinson's disease-linked mutations in VPS35 induce dopaminergic neurodegeneration.
Human Molecular Genetics, 2014, 23, 4621-38
2.1150Citations (PDF)
32A Parkinson's disease gene regulatory network identifies the signaling protein RGS2 as a modulator of LRRK2 activity and neuronal toxicity.
Human Molecular Genetics, 2014, 23, 4887-905
2.152Citations (PDF)
33Conditional expression of Parkinson's disease-related R1441C LRRK2 in midbrain dopaminergic neurons of mice causes nuclear abnormalities without neurodegeneration
Neurobiology of Disease, 2014, 71, 345-358
3.675Citations (PDF)
34LRRK2 secretion in exosomes is regulated by 14-3-3.
Human Molecular Genetics, 2013, 22, 4988-5000
2.1165Citations (PDF)
35GTPase activity regulates kinase activity and cellular phenotypes of Parkinson's disease-associated LRRK2.
Human Molecular Genetics, 2013, 22, 1140-56
2.1153Citations (PDF)
36Divergent α-synuclein solubility and aggregation properties in G2019S LRRK2 Parkinson's disease brains with Lewy Body pathology compared to idiopathic cases
Neurobiology of Disease, 2013, 58, 183-190
3.651Citations (PDF)
37Contribution of GTPase activity to LRRK2-associated Parkinson disease
Small GTPases, 2013, 4, 164-70
0.653Citations (PDF)
38GTPase Activity and Neuronal Toxicity of Parkinson's Disease–Associated LRRK2 Is Regulated by ArfGAP1
PLoS Genetics, 2012, 8, e1002526
2.2134Citations (PDF)
39PARK9-associated ATP13A2 localizes to intracellular acidic vesicles and regulates cation homeostasis and neuronal integrity
Human Molecular Genetics, 2012, 21, 1725-1743
2.1161Citations (PDF)
40Neurodegenerative phenotypes in an A53T α-synuclein transgenic mouse model are independent of LRRK2
Human Molecular Genetics, 2012, 21, 2420-2431
2.1100Citations (PDF)
41Mitochondrial Dysfunction in Genetic Animal Models of Parkinson's Disease
Antioxidants and Redox Signaling, 2012, 16, 896-919
4.287Citations (PDF)
42α-Synuclein in Central Nervous System and from Erythrocytes, Mammalian Cells, and Escherichia coli Exists Predominantly as Disordered Monomer*
Journal of Biological Chemistry, 2012, 287, 15345-15364
1.3538Citations (PDF)
43Mechanisms of LRRK2-Mediated Neurodegeneration
Current Neurology and Neuroscience Reports, 2012, 12, 251-260
4.170Citations (PDF)
44Common Pathogenic Effects of Missense Mutations in the P-Type ATPase ATP13A2 (PARK9) Associated with Early-Onset Parkinsonism
PLoS ONE, 2012, 7, e39942
1.572Citations (PDF)
45Phosphorylation of 4E-BP1 in the Mammalian Brain Is Not Altered by LRRK2 Expression or Pathogenic Mutations
PLoS ONE, 2012, 7, e47784
1.542Citations (PDF)
46Dopaminergic Neuronal Loss, Reduced Neurite Complexity and Autophagic Abnormalities in Transgenic Mice Expressing G2019S Mutant LRRK2
PLoS ONE, 2011, 6, e18568
1.5380Citations (PDF)
47Localization of MAP1-LC3 in vulnerable neurons and Lewy bodies in brains of patients with dementia with Lewy bodies.
Journal of Neuropathology and Experimental Neurology, 2011, 70, 264-80
1.561Citations (PDF)
48Parkin promotes the ubiquitination and degradation of the mitochondrial fusion factor mitofusin 1.
Journal of Neurochemistry, 2011, 118, 636-45
2.7220Citations (PDF)
49Reevaluation of Phosphorylation Sites in the Parkinson Disease-associated Leucine-rich Repeat Kinase 2*
Journal of Biological Chemistry, 2010, 285, 29569-29576
1.356Citations (PDF)
50PINK1-dependent recruitment of Parkin to mitochondria in mitophagy
Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 378-383
5.31,603Citations (PDF)
51GTPase Activity Plays a Key Role in the Pathobiology of LRRK2
PLoS Genetics, 2010, 6, e1000902
2.2197Citations (PDF)
52CHIP regulates leucine-rich repeat kinase-2 ubiquitination, degradation, and toxicity
Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 2897-2902
5.3210Citations (PDF)
53Conditional transgenic mice expressing C-terminally truncated human α-synuclein (αSyn119) exhibit reduced striatal dopamine without loss of nigrostriatal pathway dopaminergic neurons
Molecular Neurodegeneration, 2009, 4, 1-14
9.892Citations (PDF)
54Abnormal localization of leucine-rich repeat kinase 2 to the endosomal-lysosomal compartment in lewy body disease.
Journal of Neuropathology and Experimental Neurology, 2009, 68, 994-1005
1.579Citations (PDF)
55Value of genetic models in understanding the cause and mechanisms of Parkinson’s disease
Current Neurology and Neuroscience Reports, 2008, 8, 288-296
4.146Citations (PDF)
56Parkin mediates the degradation-independent ubiquitination of Hsp70.
Journal of Neurochemistry, 2008, 105, 1806-19
2.7104Citations (PDF)
57The Chaperone Activity of Heat Shock Protein 90 Is Critical for Maintaining the Stability of Leucine-Rich Repeat Kinase 2
Journal of Neuroscience, 2008, 28, 3384-3391
2.3192Citations (PDF)
58Parkinson's disease-associated mutations in LRRK2 link enhanced GTP-binding and kinase activities to neuronal toxicity
Human Molecular Genetics, 2007, 16, 223-232
2.1588Citations (PDF)
59Expression and localization of Parkinson's disease-associated leucine-rich repeat kinase 2 in the mouse brain.
Journal of Neurochemistry, 2007, 100, 368-81
2.7111Citations (PDF)
60Dynamic and redundant regulation of LRRK2 and LRRK1 expression
BMC Neuroscience, 2007, 8, 1-11
1.5147Citations (PDF)
61Localization of Parkinson’s disease-associated LRRK2 in normal and pathological human brain
Brain Research, 2007, 1155, 208-219
1.9145Citations (PDF)
62Detrimental deletions: mitochondria, aging and Parkinson's disease
BioEssays, 2006, 28, 963-967
1.736Citations (PDF)
63Localization of LRRK2 to membranous and vesicular structures in mammalian brain
Annals of Neurology, 2006, 60, 557-569
4.7508Citations (PDF)
64Lessons from Drosophila Models of DJ-1 Deficiency
Science of Aging Knowledge Environment: SAGE KE, 2006, 2006, pe2
1.029Citations (PDF)
65Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress.
Human Molecular Genetics, 2005, 14, 71-84
2.1238Citations (PDF)
66Leucine-rich repeat kinase 2 (LRRK2) interacts with parkin, and mutant LRRK2 induces neuronal degeneration
Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 18676-18681
5.3408Citations (PDF)
67Mitochondrial localization of the Parkinson's disease related protein DJ-1: implications for pathogenesis.
Human Molecular Genetics, 2005, 14, 2063-73
2.1399Citations (PDF)
68MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Annual Review of Neuroscience, 2005, 28, 57-87
7.21,200Citations (PDF)
69Parkinson's disease-associated mutations in leucine-rich repeat kinase 2 augment kinase activity
Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 16842-16847
5.31,224Citations (PDF)
70Role for the ubiquitin-proteasome system in Parkinson’s disease and other neurodegenerative brain amyloidoses
NeuroMolecular Medicine, 2003, 4, 95-108
2.252Citations (PDF)
71A missense mutation (L166P) in DJ-1, linked to familial Parkinson's disease, confers reduced protein stability and impairs homo-oligomerization.
Journal of Neurochemistry, 2003, 87, 1558-67
2.7207Citations (PDF)
72GPR105, a novel G-coupled UDP-glucose receptor expressed on brain glia and peripheral immune cells, is regulated by immunologic challenge: possible role in neuroimmune function
Molecular Brain Research, 2003, 118, 10-23
2.598Citations (PDF)
73Expression pattern of human P2Y receptor subtypes: a quantitative reverse transcription–polymerase chain reaction study
Biochimica Et Biophysica Acta Gene Regulatory Mechanisms, 2001, 1521, 107-119
3.3129Citations (PDF)
74Human R1441C LRRK2 regulates the synaptic vesicle proteome and phosphoproteome in a Drosophila model of Parkinson's disease.
Human Molecular Genetics, 0, 25, 5365-5382
2.176Citations (PDF)
75LRRK2 regulates ArfGAP1 membrane localization, activity and neuronal integrity via phosphorylation within its lipid-sensing ALPS2 motif.
Frontiers in Molecular Neuroscience, 0, 19, 1786336
2.40Citations (PDF)
76Interaction of G2019S LRRK2 and metabolic syndrome in a two-hit mouse model of Parkinson's disease: LRRK2-driven systemic depletion of pyrimidine nucleosides.
Npj Parkinson's Disease, 0
4.51Citations (PDF)
77Parkinson's disease-linked D620N mutation selectively alters the brain-specific protein interactome of VPS35.
Neurobiology of Disease, 0, 229, 107593
3.60Citations (PDF)